tiprankstipranks
Trending News
More News >
Ascendis Pharma (ASND)
NASDAQ:ASND
US Market
Advertisement

Ascendis Pharma (ASND) Stock Forecast & Price Target

Compare
623 Followers
See the Price Targets and Ratings of:

ASND Analyst Ratings

Strong Buy
17Ratings
Strong Buy
16 Buy
1 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Ascendis
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ASND Stock 12 Month Forecast

Average Price Target

$247.59
▲(25.90% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Ascendis Pharma in the last 3 months. The average price target is $247.59 with a high forecast of $307.00 and a low forecast of $203.00. The average price target represents a 25.90% change from the last price of $196.66.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","170":"$170","216":"$216","262":"$262","308":"$308"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":307,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$307.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":247.59,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$247.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":203,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$203.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,170,216,262,308],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,174.48,184.67384615384614,194.8676923076923,205.06153846153845,215.2553846153846,225.44923076923075,235.64307692307693,245.83692307692309,256.03076923076924,266.2246153846154,276.41846153846154,286.6123076923077,296.80615384615385,{"y":307,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,174.48,180.10384615384615,185.7276923076923,191.35153846153844,196.9753846153846,202.59923076923076,208.22307692307692,213.84692307692308,219.47076923076924,225.0946153846154,230.71846153846155,236.34230769230768,241.96615384615384,{"y":247.59,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,174.48,176.67384615384614,178.8676923076923,181.06153846153845,183.2553846153846,185.44923076923075,187.64307692307693,189.83692307692309,192.03076923076924,194.2246153846154,196.41846153846154,198.6123076923077,200.80615384615385,{"y":203,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":136.53,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$307.00Average Price Target$247.59Lowest Price Target$203.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on ASND
Morgan Stanley
Morgan Stanley
$250
Buy
27.12%
Upside
Reiterated
08/25/25
Ascendis Pharma (ASND) Gets a Buy from Morgan StanleyExtracted from the 'Rating, Price Target, and Estimate Changes' table row for ASND.O: Overweight with a current PT of 250.00 and a previous PT of 250.00.
J.P. Morgan Analyst forecast on ASND
J.P. Morgan
J.P. Morgan
$254$260
Buy
32.21%
Upside
Reiterated
08/19/25
Ascendis Pharma price target raised to $260 from $254 at JPMorganAscendis Pharma price target raised to $260 from $254 at JPMorgan
TR | OpenAI - 4o Analyst forecast on ASND
TR | OpenAI - 4o
TR | OpenAI - 4o
$197$205
Hold
4.24%
Upside
Reiterated
08/19/25
AI Generated ArticleAI Generated Article
Leerink Partners Analyst forecast on ASND
Leerink Partners
Leerink Partners
$200$225
Buy
14.41%
Upside
Assigned
08/11/25
Leerink Partners Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
TD Cowen Analyst forecast on ASND
TD Cowen
TD Cowen
$194$227
Buy
15.43%
Upside
Reiterated
08/08/25
Ascendis Pharma: Strong Product Performance and Growth Potential Drive Buy Rating
Wells Fargo Analyst forecast on ASND
Wells Fargo
Wells Fargo
$289$295
Buy
50.01%
Upside
Reiterated
08/08/25
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Iovance Biotherapeutics (IOVA)
Evercore ISI
$280$285
Buy
44.92%
Upside
Reiterated
08/08/25
Evercore ISI Sticks to Its Buy Rating for Ascendis Pharma (ASND)
Goldman Sachs Analyst forecast on ASND
Goldman Sachs
Goldman Sachs
$225$250
Buy
27.12%
Upside
Reiterated
08/08/25
Goldman Sachs Sticks to Their Buy Rating for Ascendis Pharma (ASND)Goldman Sachs analyst Paul Choi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $250.00 (from $225.00) while maintaining a Buy rating.
Stifel Nicolaus Analyst forecast on ASND
Stifel Nicolaus
Stifel Nicolaus
$212$254
Buy
29.16%
Upside
Reiterated
08/08/25
Stifel Nicolaus Sticks to Their Buy Rating for Ascendis Pharma (ASND)
Oppenheimer Analyst forecast on ASND
Oppenheimer
Oppenheimer
$224$246
Buy
25.09%
Upside
Reiterated
08/08/25
Oppenheimer Remains a Buy on Ascendis Pharma (ASND)
UBS
$306$307
Buy
56.11%
Upside
Reiterated
08/08/25
Ascendis Pharma price target raised to $307 from $306 at UBSAscendis Pharma price target raised to $307 from $306 at UBS
Cantor Fitzgerald Analyst forecast on ASND
Cantor Fitzgerald
Cantor Fitzgerald
$200$203
Buy
3.22%
Upside
Reiterated
08/08/25
Cantor Fitzgerald Sticks to Their Buy Rating for Ascendis Pharma (ASND)
Wedbush Analyst forecast on ASND
Wedbush
Wedbush
$212$220
Buy
11.87%
Upside
Reiterated
08/08/25
Wedbush Remains a Buy on Ascendis Pharma (ASND)
RBC Capital Analyst forecast on ASND
RBC Capital
RBC Capital
$210$230
Buy
16.95%
Upside
Reiterated
08/08/25
Ascendis Pharma (ASND) Gets a Buy from RBC Capital
Citi
$243$290
Buy
47.46%
Upside
Reiterated
08/07/25
Ascendis Pharma price target raised to $290 from $243 at CitiAscendis Pharma price target raised to $290 from $243 at Citi
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on ASND
Morgan Stanley
Morgan Stanley
$250
Buy
27.12%
Upside
Reiterated
08/25/25
Ascendis Pharma (ASND) Gets a Buy from Morgan StanleyExtracted from the 'Rating, Price Target, and Estimate Changes' table row for ASND.O: Overweight with a current PT of 250.00 and a previous PT of 250.00.
J.P. Morgan Analyst forecast on ASND
J.P. Morgan
J.P. Morgan
$254$260
Buy
32.21%
Upside
Reiterated
08/19/25
Ascendis Pharma price target raised to $260 from $254 at JPMorganAscendis Pharma price target raised to $260 from $254 at JPMorgan
TR | OpenAI - 4o Analyst forecast on ASND
TR | OpenAI - 4o
TR | OpenAI - 4o
$197$205
Hold
4.24%
Upside
Reiterated
08/19/25
AI Generated ArticleAI Generated Article
Leerink Partners Analyst forecast on ASND
Leerink Partners
Leerink Partners
$200$225
Buy
14.41%
Upside
Assigned
08/11/25
Leerink Partners Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
TD Cowen Analyst forecast on ASND
TD Cowen
TD Cowen
$194$227
Buy
15.43%
Upside
Reiterated
08/08/25
Ascendis Pharma: Strong Product Performance and Growth Potential Drive Buy Rating
Wells Fargo Analyst forecast on ASND
Wells Fargo
Wells Fargo
$289$295
Buy
50.01%
Upside
Reiterated
08/08/25
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Iovance Biotherapeutics (IOVA)
Evercore ISI
$280$285
Buy
44.92%
Upside
Reiterated
08/08/25
Evercore ISI Sticks to Its Buy Rating for Ascendis Pharma (ASND)
Goldman Sachs Analyst forecast on ASND
Goldman Sachs
Goldman Sachs
$225$250
Buy
27.12%
Upside
Reiterated
08/08/25
Goldman Sachs Sticks to Their Buy Rating for Ascendis Pharma (ASND)Goldman Sachs analyst Paul Choi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $250.00 (from $225.00) while maintaining a Buy rating.
Stifel Nicolaus Analyst forecast on ASND
Stifel Nicolaus
Stifel Nicolaus
$212$254
Buy
29.16%
Upside
Reiterated
08/08/25
Stifel Nicolaus Sticks to Their Buy Rating for Ascendis Pharma (ASND)
Oppenheimer Analyst forecast on ASND
Oppenheimer
Oppenheimer
$224$246
Buy
25.09%
Upside
Reiterated
08/08/25
Oppenheimer Remains a Buy on Ascendis Pharma (ASND)
UBS
$306$307
Buy
56.11%
Upside
Reiterated
08/08/25
Ascendis Pharma price target raised to $307 from $306 at UBSAscendis Pharma price target raised to $307 from $306 at UBS
Cantor Fitzgerald Analyst forecast on ASND
Cantor Fitzgerald
Cantor Fitzgerald
$200$203
Buy
3.22%
Upside
Reiterated
08/08/25
Cantor Fitzgerald Sticks to Their Buy Rating for Ascendis Pharma (ASND)
Wedbush Analyst forecast on ASND
Wedbush
Wedbush
$212$220
Buy
11.87%
Upside
Reiterated
08/08/25
Wedbush Remains a Buy on Ascendis Pharma (ASND)
RBC Capital Analyst forecast on ASND
RBC Capital
RBC Capital
$210$230
Buy
16.95%
Upside
Reiterated
08/08/25
Ascendis Pharma (ASND) Gets a Buy from RBC Capital
Citi
$243$290
Buy
47.46%
Upside
Reiterated
08/07/25
Ascendis Pharma price target raised to $290 from $243 at CitiAscendis Pharma price target raised to $290 from $243 at Citi
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ascendis Pharma

1 Month
xxx
Success Rate
12/16 ratings generated profit
75%
Average Return
+6.33%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +6.33% per trade.
3 Months
xxx
Success Rate
20/26 ratings generated profit
77%
Average Return
+10.31%
assigned a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +10.31% per trade.
1 Year
Tazeen AhmadBank of America Securities
Success Rate
26/30 ratings generated profit
87%
Average Return
+26.59%
reiterated a buy rating 21 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +26.59% per trade.
2 Years
xxx
Success Rate
16/16 ratings generated profit
100%
Average Return
+58.23%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +58.23% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ASND Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
9
7
7
9
8
Buy
22
23
30
40
44
Hold
13
8
3
2
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
44
38
40
51
56
In the current month, ASND has received 52 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ASND average Analyst price target in the past 3 months is 247.59.
Each month's total comprises the sum of three months' worth of ratings.

ASND Financial Forecast

ASND Earnings Forecast

Next quarter’s earnings estimate for ASND is -$0.31 with a range of -$1.46 to $0.34. The previous quarter’s EPS was -$0.96. ASND beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year ASND has Outperformed its overall industry.
Next quarter’s earnings estimate for ASND is -$0.31 with a range of -$1.46 to $0.34. The previous quarter’s EPS was -$0.96. ASND beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year ASND has Outperformed its overall industry.

ASND Sales Forecast

Next quarter’s sales forecast for ASND is $244.92M with a range of $209.08M to $274.86M. The previous quarter’s sales results were $179.27M. ASND beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year ASND has Outperformed its overall industry.
Next quarter’s sales forecast for ASND is $244.92M with a range of $209.08M to $274.86M. The previous quarter’s sales results were $179.27M. ASND beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year ASND has Outperformed its overall industry.

ASND Stock Forecast FAQ

What is ASND’s average 12-month price target, according to analysts?
Based on analyst ratings, Ascendis Pharma’s 12-month average price target is 247.59.
    What is ASND’s upside potential, based on the analysts’ average price target?
    Ascendis Pharma has 25.90% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ASND a Buy, Sell or Hold?
          Ascendis Pharma has a consensus rating of Strong Buy which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Ascendis Pharma’s price target?
            The average price target for Ascendis Pharma is 247.59. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $307.00 ,the lowest forecast is $203.00. The average price target represents 25.90% Increase from the current price of $196.66.
              What do analysts say about Ascendis Pharma?
              Ascendis Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of ASND?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis